© Drug Hunter Inc. 2018-2023
Home > “compound 4d”
oral selective PI3K_ kinase inhibitor
<10 mg proj. human dose
from virtual screening and opt.
ACS Med. Chem. Lett., Nov. 19, 2020
Merck, Boston, CA
“compound 4d” (Merck oral selective PI3K delta kinase inhibitor)
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.
Molecules of the Month
Molecule of the Year